Justin Schreiber Acquires 17,664 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD – Get Rating) CEO Justin Schreiber acquired 17,664 shares of the stock in a transaction dated Monday, May 22nd. The shares were purchased at an average price of $2.15 per share, for a total transaction of $37,977.60. Following the completion of the purchase, the chief executive officer now directly owns 2,812,284 shares in the company, valued at $6,046,410.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

LifeMD Stock Performance

Shares of LFMD opened at $2.17 on Friday. LifeMD, Inc. has a 52 week low of $1.14 and a 52 week high of $3.22. The firm has a market cap of $70.33 million, a P/E ratio of -1.72 and a beta of 1.30. The firm’s 50-day simple moving average is $1.66 and its 200 day simple moving average is $1.91.

LifeMD (NASDAQ:LFMD – Get Rating) last announced its quarterly earnings results on Wednesday, March 22nd. The company reported ($0.40) EPS for the quarter. LifeMD had a negative net margin of 29.44% and a negative return on equity of 7,255.81%. The company had revenue of $28.12 million during the quarter.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new position in shares of LifeMD during the 1st quarter worth approximately $151,000. Jane Street Group LLC grew its position in shares of LifeMD by 425.0% during the 4th quarter. Jane Street Group LLC now owns 73,517 shares of the company’s stock worth $143,000 after purchasing an additional 59,513 shares in the last quarter. Millennium Management LLC bought a new stake in shares of LifeMD during the 4th quarter worth approximately $106,000. Bank of New York Mellon Corp bought a new stake in shares of LifeMD during the 3rd quarter worth approximately $64,000. Finally, Virtu Financial LLC bought a new stake in shares of LifeMD during the 4th quarter worth approximately $62,000. Institutional investors and hedge funds own 17.01% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BTIG Research lowered their price objective on shares of LifeMD from $8.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, March 23rd.

LifeMD Company Profile

(Get Rating)

LifeMD, Inc is a telehealth company, which engages in offering a portfolio of direct-to-patient products and services. The firm combines virtual medical treatment with prescription medications and over-the-counter products. It operates through the Telehealth and WorkSimpli segments. The company was founded in 1987 and is headquartered in New York, NY.